Intellia Therapeutics

First-of-its-kind Intellia data suggest CRISPR drug could be given more than once
BioPharma Dive
Wed, 06/26/24 - 10:00 am
Intellia Therapeutics
CRISPR
gene editing
transthyretin amyloidosis
Intellia, ReCode partner on genetic medicines for cystic fibrosis
BioPharma Dive
Thu, 02/15/24 - 11:33 am
Intellia Therapeutics
cystic fibrosis
ReCode
genetic medicine
Intellia’s CRISPR drug could offer one-shot HAE treatment
Pharmaphorum
Thu, 02/1/24 - 11:26 am
Intellia Therapeutics
HAE
clinical trials
CRISPR
gene editing
NTLA-2002
Intellia to lay off staff, cut some early research
BioPharma Dive
Fri, 01/5/24 - 09:51 am
Intellia Therapeutics
layoffs
gene editing
Intellia Gets FDA Clearance to Start First Ever Phase III Trial for an In Vivo CRISPR Drug
Xtalks
Mon, 10/23/23 - 10:31 am
Intellia Therapeutics
FDA
NTLA-2001
ATTR with cardiomyopathy
CRISPR on the Cusp: The Promise and the Pain Points
BioSpace
Mon, 07/10/23 - 09:27 pm
Intellia Therapeutics
HAE
NTLA-2002
CRISPR
Patients attack-free a year after receiving Intellia's hereditary angioedema CRISPR med
Fierce Biotech
Sun, 06/11/23 - 11:07 pm
Intellia Therapeutics
HAE
hereditary angiodema
CRISPR
NTLA-2002
Gene Editing Therapeutics Could Hit the Market in 2023
BioSpace
Mon, 04/10/23 - 11:32 am
gene editing
CRISPR Therapeutics
Vertex Pharmaceuticals
Intellia Therapeutics
Editas Medicine
Beam Therapeutics
Intellia Seeks to Broaden Gene Editing’s Potential with Full-Spectrum Approach
BioSpace
Mon, 04/3/23 - 09:55 am
gene editing
Intellia Therapeutics
Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing
Investors Business Daily
Fri, 03/3/23 - 11:46 am
Intellia Therapeutics
CRISPR
FDA
Novartis Drops SCD Gene Therapy Program with Intellia
BioSpace
Fri, 02/24/23 - 09:03 am
Novartis
sickle cell disease
Intellia Therapeutics
CRISPR
gene editing
Biotech’s key upcoming clinical results
EP Vantage
Tue, 12/20/22 - 10:27 am
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
10 Massachusetts Biopharma Companies Hiring Now
BioSpace
Fri, 12/2/22 - 11:18 am
Massachusetts
hirings
AbbVie
Moderna Therapeutics
CSL
Intellia Therapeutics
Schrödinger
Visterra
Alloy Therapeutics
Werewolf Therapeutics
Sherlock Biosciences
The gloom deepens for biopharma stocks
EP Vantage
Mon, 10/10/22 - 06:54 pm
biopharma stocks
AbbVie
Alnylam
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eisai
Eli Lilly
GSK
Intellia Therapeutics
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Intellia's Latest Data Indicate Full Potential of CRISPR
BioSpace
Sun, 09/18/22 - 10:31 pm
Intellia Therapeutics
ATTR amyloidosis
hereditary angiodema
CRISPR
Intellia's gene editing therapies both post early successes as evidence grows for CRISPR potential
Fierce Biotech
Fri, 09/16/22 - 10:53 am
Intellia Therapeutics
gene editing
NTLA-2001
ATTR amyloidosis
clinical trials
Regeneron
Big Pharma partnerships, record $22.7B investment raise profile of regenerative medicine in 2021
Fierce Biotech
Tue, 04/5/22 - 11:41 pm
regenerative medicine
gene editing
gene therapy
Big Pharma
Intellia Therapeutics
Intellia's CRISPR-engineered cell therapy secures FDA orphan drug status after AML trial launch
Fierce Biotech
Wed, 03/9/22 - 11:13 pm
Intellia Therapeutics
CRISPR
FDA
cell therapy
orphan drugs
Intellia presses forward with new results for pioneering CRISPR drug
BioPharma Dive
Mon, 02/28/22 - 11:46 pm
Intellia Therapeutics
CRISPR
transthyretin amyloidosis
Intellia follows CRISPR peers with deal to explore 'natural killer' cell therapy
BioPharma Dive
Tue, 02/15/22 - 11:28 pm
Intellia Therapeutics
ONK Therapeutics
natural killer cell therapy
immunotherapy

Pages